These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26683709)

  • 1. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.
    Jiang T; Wang Y; Zhou F; Gao G; Ren S; Zhou C
    Oncotarget; 2016 Jan; 7(4):4584-97. PubMed ID: 26683709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
    Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y
    Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
    Chen S; Huang L; Sun K; Wu D; Li M; Li M; Zhong B; Chen M; Zhang S
    PLoS One; 2015; 10(5):e0125480. PubMed ID: 25974088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
    Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
    Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
    Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
    Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
    Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
    Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 expression in invasive lobular carcinoma of the breast.
    Roh S; Park SY; Ko HS; Sohn JS; Cha EJ
    World J Surg Oncol; 2013 Nov; 11():299. PubMed ID: 24266940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
    Panousis D; Xepapadakis G; Lagoudianakis E; Karavitis G; Salemis N; Koronakis N; Patsouris E; Koronarchis D; Grosomanidis D; Chryssikos G; Ntasiou P; Kyriakidou V; Athanassiadou AM; Athanassiadou P
    J BUON; 2013; 18(4):879-85. PubMed ID: 24344012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
    Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
    Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma.
    Chen SQ; Zhang HM; Li JB; Jiang HY; Fan L; Kong LZ; Yao SZ
    Int J Gynecol Cancer; 2014 Nov; 24(9):1653-8. PubMed ID: 25275664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.
    Pang J; Toy KA; Griffith KA; Awuah B; Quayson S; Newman LA; Kleer CG
    Breast Cancer Res Treat; 2012 Aug; 135(1):59-66. PubMed ID: 22527102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of EZH2 in breast cancer and its clinicopathological significance].
    Liu J; Wang H; Deng Y; Cao P; Li X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 42(4):443-9. PubMed ID: 24022934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
    Ha SY; Kim SH
    Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
    Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
    Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.